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Summary 
Nitric oxide (NO) generated by the inducible isoform of NO synthase (iNOS) is required for 
the resolution of acute cutaneous leishmaniasis in resistant C57BL/6 mice. As is the case in sev- 
eral other infections, the clinically cured host organism still harbors small amounts of  live Leish- 
mania major parasites. Here, we demonstrate lifelong expression of iNOS at the site of the orig- 
inal skin lesion and in the draining lymph node of long-term-infected C57BL/6 mice. iNOS 
activity in the lymph node was dependent on CD4 +, but not on CD8 + T  cells. By double la- 
beling techniques, iNOS and L. major  were each found in macrophages (F4/80 +, BM-8 +, and/ 
or MOMA-2 +) and dendritic cells (NLDC-145+), but not in granulocytes or endothelial cells. 
In situ triple labeling of lymph node sections revealed that "-'30-40% of the L. major foci were 
associated with iNOS-positive macrophages or dendritic cells. The majority of the L. major  foci 
(60-70%),  however, was located in areas that were negative for both iNOS and the macro- 
phage and dendritic cell markers. In L.  major-infected  C57BL/6 mice, which had cured their 
cutaneous lesions,  administration of t-Nt-iminoethyl-lysine 0.-NIL),  a  potent  inhibitor  of 
iNOS, led to a 104-10S-fold increase of the parasite burden in the cutaneous and lymphoid tis- 
sue and caused clinical recrudescence of the disease. Persistent expression ofiNOS and resump- 
tion of parasite  replication after application oft-NIL was also observed in resistant C3H/HeN 
and CBA/J mice. We conclude that iNOS activity is crucial for the control of Leishmania per- 
sisting in immunocompetent hosts after resolution of the primary infection. Failure to maintain 
iNOS activity might be the mechanism underlying endogenous reactivation of latent infections 
with NO-sensitive microbes during phases ofimmunosuppression. 
C 
ure of acute infections with intracellular microorgan- 
isms is dependent on the activation of static  or cidal 
mechanisms in the infected host cells. The armamentarium, 
which is brought up by the host when encountering disease- 
mediating microbes, consists of constitutively expressed  03,_ 
sosomal) proteases, peroxidative enzymes, cytotoxic polypep- 
tides, and several  cytokine-inducible antimicrobial effector 
pathways (1, 2). Among the latter, the high level synthesis 
of nitric oxide (NO) 1 from L-arginine by the inducible iso- 
form of NO synthase (iNOS, NOS-2)  has been shown to 
be indispensable for the defense against a growing spectrum 
1Abbreviations used in thispaper: (i)NOS, (inducible  isoform  of) nitric oxide 
synthase (NOS-2; independent of exogenous calmodulin and  [Ca  2+] 
above the levels in resting cells); I,=NAME, L-N<;-nitroarginine-methyl  - 
ester; I,-NIL, I.=N~-(1-iminoethyl)=lysine;  I,-NMMA, /~=monomethyl- 
L-arginine; NADPH, nicotinamide  adenine dinudeotide phosphate (re- 
duced form);  NO, nitric oxide; RT, room temperature. 
This work was presented in part at the 9th International  Congress  of Im- 
munology  in San Francisco, CA on 23-29 July 1995. 
of viruses,  bacteria, protozoa, fungi, and helminths (3, and 
references therein). The antimicrobial role of NO (and re- 
lated nitrogen intermediates) generated by iNOS was ini- 
tially established  in vitro where the killing of microbes by 
cytokine-activated macrophages correlated with the release 
of NO  and was  abrogated by  nonselective inhibitors  of 
NOS (which block the activity of  both the constitutive and 
the inducible isoform of the enzyme) (3). In vivo, several 
infections took a  more  severe,  nonhealing course,  when 
iNOS was inhibited by isoform-selective or -nonselective 
antagonists (4, and references therein) or genetically deleted 
in mice (5, 6). Furthermore, in several disease models, en- 
hanced  expression  of iNOS  was paralleled by a  reduced 
number of microorganisms in the tissue and vice versa (7-9). 
Although NO  was reported to be  directly toxic to some 
parasites, e.g., Leishmania major (10,  11), it should be men- 
tioned that the vast majority of data published so far is also 
compatible with an  indirect antimicrobial effect of NO, 
which, for example, could be exerted by its signal transduc- 
tion  function  (12).  This  possibility,  however,  does  not 
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of a large number of infectious diseases. 
Whereas  the  function  of iNOS  in vitro and  during  the 
acute phase of infections with intracellular microorganisms 
is fairly well studied  in  the  mouse system, little  is known 
about its role during latent infections in vivo. Several bac- 
teria or protozoa (e.g., Mycobacterium tuberculosis, Toxoplasma 
gondii, Leishmania spp.) continue  to reside in small numbers 
within  immunocompetent  hosts  after clinical  cure  of the 
disease, which bears the risk of endogenous  reactivation of 
the infection later in life whenever cell-mediated immunity 
becomes  suppressed  (13-17).  At least in  mice,  healing  or 
control  of these  diseases is paralleled  by the  expression  of 
iNOS in the tissue and clearly requires the presence of NO 
(7, 9, 10,  18,  19). Nevertheless, the host fails to completely 
eliminate the microorganisms. This suggests that during la- 
tent  infection,  the  persisting  microbes  may acquire  resis- 
tance to NO  and that other antimicrobial mechanisms be- 
come activated and inhibit  replication,  but do  not lead to 
eradication  of the bacteria and/or parasites. We decided to 
test this possibility using the L.  major mouse model, where 
resistant strains continue  to harbor a small amount of para- 
sites  throughout  life  (16,  20-24)  despite  NO-dependent 
healing of the  cutaneous  lesions  during the  acute phase of 
infection (4, 10, 18). By in situ analysis and inhibitor exper- 
iments,  we  demonstrate  that expression  of iNOS  is main- 
tained lifelong in chronically infected but clinically healthy 
mice and is absolutely crucial for the continuous  control of 
the Leishmania.  Our data do not provide evidence that the 
persisting parasites are dormant or become resistant to NO, 
but rather suggest a dynamic process in the host tissue with 
alternating phases of parasite killing and evasion. 
Materials and Methods 
Animals, Parasites,  and In Vivo  Infection.  Female BALB/c, C57BL/6, 
CBA/J, C3H/HeN, and CD1 mice were purchased from Charles 
RAver Breeding Laboratories (Sulzfeld,  Germany), kept on a nor- 
real rodent diet, and used for infection at 8-10 wk of age. Origin, 
in vivo passage,  and in vitro propagation of the L.  major isolate 
(MHOM/IL/81/FE/BNI)  were as reported previously (9). Mice 
were routinely inoculated into the right hind footpad with 3  ￿ 
106 stationary phase L.  major promastigotes (after two to four in 
vitro subcultures). In some experiments, mice were infected bilat- 
erally into  both hind  footpads.  This  allowed processing of the 
footpad tissue  from one  animal for both immunohistology and 
PCtL.  At  regular intervals  after infection,  the  footpad swelling 
was measured with a metric caliper (9). The number of parasites 
in the tissue of infected mice was determined by limiting dilution 
analysis (with serial 10-fold dilutions of the tissue seeded into 96- 
well plates with Novy-Nicolle-MacNeal blood agar slants) apply- 
ing Poisson  statistics  and ￿  method  as published 
earlier (9, 22). 
In  Vivo Treatment of Long-Term-Infected, Clinically Cured Mice. 
Genetically resistant mice (C57BL/6, CBA/J, C3H/HeN) or sus- 
ceptible  mice  (BALB/c)  made  resistant  by application  of anti- 
CD4  or IL-12 or low dose inoculation  with L.  major resolved 
their skin lesions  within 50-70 d after infection. Treatment with 
NOS inhibitors or Abs was not started before day 103 after pri- 
mary infection. The NOS inhibitors were added to the drinking 
water  (adjusted  to  pH  2.7  to  prevent  microbial  growth)  and 
fleshly provided every second day. Food and water uptake as well 
as body weight were recorded throughout the treatment. Mono- 
clonal anti-CD4 (YTS 191.1)  or anti-CD8 Ab (YTS 169.2),  pre- 
pared by ammonium sulphate precipitation of rat ascites fluid and 
subsequent dialysis against PBS, were injected at 2-4-d intervals 
(200 or 500 p,g i.p. per dose, respectively). 
NOS lnhibitors and Other Reagents.  The reduced form of nico- 
tinamide dinudeotide phosphate (NADPH), flavin adenin dinude- 
otide (FAD), L-arginine hydrochloride, pepstatin A, chymostatin, 
and PMSF were obtained from Sigma Chemie (Deisenhofen, Ger- 
many).  (6R-)  tetrahydrobiopterin  (I3I-I4) was  purchased  from 
Dr. Schircks  Co.  (Jona,  Switzerland),  the t  and D analogues of 
N~-monomethyl-arginine  (L-NMMA,  D-NMAMA) and  of N ~- 
nitro-arginine-methyl-ester  (L-NAME,  D-NAME)  were  from 
Alexis Co. (IAufelfingen, Switzerland). The t-/Vs-(1-iminoethyl) 
lysine (L-NIL) was synthesized and kindly provided by Drs. Pare 
Manning, W.M. Moore, and M.G. Currie (G.D. Searle lLesearch 
and Development, Monsanto Co., St. Louis, MO). 
Abs for FACS  ~ Analysis,  Immunofluorescence, and lmmunohistol- 
ogy.  FITC-conjugated rat mAb against CD4 (clone YTS191.1), 
CD8 (done YTS169.4), B220 (done RA3-6B2), Mac-1/CDllb 
(clone M1/70.15),  and mouse mAb against  Thyl.2  (done 5a-8) 
were  obtained  from Medac  Inc.  (Hamburg,  Germany).  FITC- 
conjugated  rat  mAb  against  F4/80-antigen  was  from  Serotec/ 
Camon  (Wiesbaden,  Germany).  A  FITC-conjugated  rat  mAb 
NLDC-145  (IgG2a, dendritic  cells) was obtained by protein  G 
aflSnity chromatography ofNLDC-145 hybridoma culture super- 
natants and subsequent  FITC labehng  (Boehringer,  Mannheim, 
Germany) of the purified Ab following the manufacturer's protocol. 
A polydonal rabbit anti-L, major  antiserum (9) was generously sup- 
plied by Dr. H. Moll (Zentmm flir Infektionsforschung,  Wtirzburg, 
Germany).  Human anti-/.,  major antiserum was from a patient 
with multilesional cutaneous leishrnaniasis  (25). Pilot experiments 
with serial sections from the skin lesions  and lymph nodes of L. 
major-infected  mice established  that the rabbit and the human an- 
tiserum recognized L. major parasites  equally well. A rabbit anti- 
mouse  iNOS  antiserum  raised  against  an  octapeptide  derived 
from the COOH terminus of  the mouse iNOS sequence (NOS-16) 
was kindly provided by ITrs. Q.-w. Xie and C. Nathan (Comell 
University Medical College, New York) and by Drs. J. Weidner 
and R.  Mumford  (Merck,  l~ahway,  NJ).  The rat mAbs BM-8 
(IgG2a; mature tissue  macrophages), M1/70.15  (IgG2b; CDllb 
antigen  [Mac-l]  on  macrophages,  granulocytes,  and  NK cells), 
C1.A.3-1  (IgG2b; F4/80 antigen  on monocytes and tissue macro- 
phages), MOMA-2 (IgG2b; monocytes, tmgible body macrophages, 
and macrophages in T  cell-dependent areas), R.B6-8C5  (IgG2b; 
GtL-1 antigen on granulocytes),  and NLDC-145 (IgG2a; dendritic 
cells in skin, spleen, and lymph node) were all purchased from Di- 
anova Inc. (Hamburg, Germany). A rat mAb (MECA-32) specific 
for routine endothelial ceils (26) was kindly provided by Dr. R. Hall- 
mann (Institut fiir Experimentelle Medizin, Erhngen, Germany). 
Isolation of Cells and Tissue.  For quantification  of the parasite 
load with  the  limiting dilution  technique,  homogenates  of the 
skin lesion or single cell suspensions of the draining lymph nodes 
were prepared as described (9, 22).  For determination of the cel- 
lular  composition  of lymph  nodes  by flow  cytometry using  a 
FACScan  |  (Becton Dickinson & Co., Mountain View, CA), the 
organs were gently crushed between two glass slides in order to 
obtain single cell suspensions.  For isolation of total KNA, organs 
were flash frozen in liquid nitrogen and stored at -70~  while 
the  contralateral  tissue  samples  were  embedded  in  specimen 
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compound (Diatec, Hallstadt/Bamberg, Germany) and stored fro- 
zen for later immunohistological analysis. For iNOS enzyme ac- 
tivity assays, the lymph nodes from L. major-infected mice were 
first flash frozen and later disrupted in lysis buffer (40 mM Tris, 
pH 8, 5 ~g/ml pepstatin A, 1 ~g/ml chymostatin, 5 ~g/ml apro- 
tinin,  10 /.~M leupeptin,  100 IzM PMSF) by sonication  with a 
Sonifier  B-12  (Branson Ultrasonics,  Heinemann  Company, 
Schw~ibisch-Gmiind, Germany; 2 ￿  30 s at intensity 2), 
Detection of iNOS by Double Immunofluorescence.  Single  cell sus- 
pensions were prepared from lymph nodes of  long-term-infected 
C57BL/6 mice and, in some experiments, partially depleted ofT 
and B cells by magnetic cell separation with a Macs  |  column (Mil- 
tenyi  Biotech,  Bergisch-Gladbach,  Germany)  after  incubation 
with anti-Thyl.2 and anti-B220 Abs coupled to magnetic parti- 
cles. Cells were allowed to attach for 30 min on adhesion slides 
(Bio-Kad, Munich, Germany). For detection of cell surface anti- 
gens,  cells were  incubated  with  FITC-conjugated  F4/80  or 
NLDC-145 rat mAb diluted in PBS/0.1% BSA/0.01% NaN  a (30 
rain, 4~  before fixation with ice-cold acetone (7-8 rain). Cells 
were then incubated with rabbit anti-iNOS peptide (NOS-16; 45 
min at room temperature [KT]) followed by lissamine-rhodamine-- 
conjugated  F(ab')2 fragments  of donkey anti-rabbit  IgG  (Di- 
anova; 30-45 rain, KT), both diluted in PBS/0.1% BSA/1% sa- 
ponin.  Ceils were examined by using an Axiophote microscope 
(Zeiss, Oberkochen, Germany) equipped with appropriate fluo- 
rescence filters. 
Immunoenzymatic Staining of Tissue Sections.  5-~M  tissue sec- 
tions  prepared  with  a  cryostat  (model  HM500;  Fa.  Microm, 
WaUstadt, Germany) were thawed onto gelatin-coated slides, air- 
dried for 60 rain, and fixed in acetone (for 10 rain,  at -20~ 
The  remaining  OCT  compound was  washed  off with  PBS/ 
0.05% Tween 20 and nonspecific binding sites were blocked by 
incubation in PBS containing 1% BSA and 20% FCS (for 30 rain 
at room temperature). 
Staining of a single antigen (iNOS,  cell type or L. major) was 
performed exactly as described (9). For double labeling, a combi- 
nation of  gold-silver immunostaining (for detection ofiNOS) and 
immunoenzymatic labeling (for detection of L. major  or cell type) 
was performed exactly as published previously (9). In some cases we 
used  streptavidin-biotin-peroxidase  complex (with  3-amino-9- 
ethylcarbazole [AEC] as substrate) instead of streptavidin-biotin- 
alkaline phosphatase complex (with Fast blue BB salt as substrate) 
for the immunoenzymatic  labeling (9). For triple labeling, gold- 
silver immunostaining  (for detection of iNOS)  was  combined 
with peroxidase and alkaline phosphatase immunoenzymatic  la- 
beling (for detection of cell type or L. major, respectively). After 
blocking, the following sequence of treatments and incubations 
was used (3 X 10 rain washing with PBS/0.05% Tween 20 be- 
tween steps 1 and 2 and 4 and 8 or with 50 mM Tris, pH 8.2/ 
0.05% Tween 20 between steps 2 and 4; brief washing with dis- 
tilled water between steps 8 and 10): (step 1) simultaneous addi- 
tion of  all three primary Abs (rabbit anti-iNOS, rat anti-cell type, 
human anti-L, major, overnight,  4~  (step 2) gold-conjugated 
goat anti-rabbit IgG (Dako, Hamburg, Germany; 1 h, RT); (step 3) 
attinity-purified alkaline phosphatase-conjugated F(ab')2 fragment 
goat anti-human-IgG (1 h, KT); (step 4) development with Fast 
blue BB salt substrate solution (5-20 rain, KT); (step 5) attlnity- 
purified, biotin-conjugated  F(ab')2 fragment mouse anti-rat-IgG 
(1 h, RT); (step 6) streptavidin-biotin-peroxidase  complex (lh, 
R.T); (step 7)  development with AEC  substrate solution  (5-10 
min, I~T); (step 8) postfixation with 2% glutaraldehyde in PBS 
(10 rain, 4~  (step 9) quenching of  aldehyde groups with 0.05 M 
glycine in PBS (10 min, 4~  and (step 10) treatment with im- 
munogold-silver  enhancement  mixture  (Amersham, Braunsch- 
weig,  Germany)  (one to five incubation  periods  of 3-10 min 
each,  RT).  After  brief rinsing  in  distilled  water,  slides were 
mounted without counterstaining.  In  control experiments,  no 
staining was obtained when any of  the primary Ab was combined 
with an irrelevant secondary reagent  used in the triple staining 
procedure,  or when the primary Abs were replaced by preim- 
mune sera or an irrelevant isotype-matched control Ab. NADPH 
diaphorase staining was performed as described (9). 
RNA  Preparatzbn and  Competitive Reverse Transcriptase--PCR. 
RNA was prepared by the guanidinium  isothiocyanate method 
and reverse transcribed as described (9). iNOS or I;t-actin cDNA 
was amplified and quantitated by competitive PCR technique us- 
ing primers specific for iNOS or ~-actin in the presence of de- 
fined dilutions of  the respective competitor plasmids as reported re- 
cently (9). 
Determination of iNOS Enzyme Activity.  iNOS enzyme activ- 
ity in total lymph node lysates (40-60 lig) was measured in a mi- 
croplate assay exactly as described (27). 
Results 
Lifelong Expression  of iNOS mRNA,  Protein, and Activity 
in the Tissue of L. major-infected C57BL/6 Mice.  In  a  pre- 
vious study with L. major-infected, resistant C57BL/6 mice, 
we demonstrated that the  onset of parasite reduction and 
healing of the cutaneous lesions coincided with an upregu- 
lation of iNOS in the dermis of the skin lesion and in the 
draining lymph node (9). Immunohistological analysis of  the 
footpad (Fig. 1, A and/3) and the popliteal lymph node from 
C57BL/6 mice (Fig.  1,  C-H)  at various time points after 
resolution of clinical disease revealed that the expression of 
iNOS protein remained at high levels, despite a  103-106- 
fold decrease of the parasite burden, respectively (Fig. 2 A). 
No staining for iNOS was obtained in the presence of 1-10 
p,g/ml of the iNOS peptide used for generating the poly- 
clonal rabbit antiserum (Fig.  1, E and F) or when the tissue 
sections were incubated with the respective rabbit preim- 
mune serum (not shown). Persistence of iNOS protein in 
long-term-infected C57BL/6  mice  (>day  100  of infec- 
tion) was found in 34 of 38 skin lesions and in all of 78 ex- 
amined lymph nodes, which were derived from 20 inde- 
pendent time course experiments. 26 (skin) and 44 (lymph 
node) individual time points (>day 100) were investigated, 
the  latest being day 766  after infection.  Whereas  in  the 
draining  lymph  node  virtually  every 5-p~M  section  was 
positive for iNOS, the expression was much more focal in 
the dermis of the former skin lesion. No iNOS protein was 
detected in the spleen of long-term-infected mice or in the 
lymphoid  tissue  of  age-matched  uninfected  mice  (not 
shown). 
Three additional experimental approaches confirmed the 
persistent expression ofiNOS in the tissue beyond the acute 
phase of  infection. By competitive reverse transcriptase-PCtL 
analysis,  the  amount  of iNOS  mRNA  in  the  tissue  re- 
mained at comparable levels between days 35  and 252 of 
infection (Fig. 2 B). Similarly, the specific activity of NOS 
in  the lymph  nodes  of L.  major-infected  C57BL/6  mice 
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Figure 2.  Lesion  size, parasite burden, and tissue 
expression of iNOS mlLNA during the course of 
L. major  infection in C57BL/6 mice. 16 (A) or 15 
(B) mice were infected bilaterally with L. major  into 
the hind footpads. (A) Development of  the footpad 
lesions  (mean increase of footpad thickness -+ 
SEM). Parasite burden in the pooled organs of  two 
to three mice was determined by limiting dilution 
analysis at various time points a~er infection. The 
contralateral organs were processed for iNOS im- 
munohistochemistry  (not  shown).  (/3')  iNOS 
mRNA was quantitated in the pooled organs of 
three mice by competitive RT-PCR analysis. 
was in the same order of magnitude before and after heal- 
ing of the cutaneous lesions (Table 1). Finally, as previously 
shown for the acute stage of infection (9), we again found a 
perfect  colocalization  between  iNOS  (detected  by  anti- 
iNOS  immunostaining)  and  NADPH-diaphorase  activity 
in the skin (not shown) and draining lymph node of longo 
term-infected  mice  (Fig.  1,  G  and/q).  This  further indi- 
cates the presence of functionally active iNOS. 
Persistence of iNOS Is a More General Phenomenon Also Ob- 
sewed in other Mouse Strains.  We  envisaged  the  possibility 
that the continuous expression ofiNOS, despite clinical heal- 
hag of the disease, is unique for the C57BL/6 mouse strain, 
which  shows  an  intermediate  resistance  to  L.  major  (28) 
without complete clearance of the parasites from the tissue 
(23,  and  Fig.  2  A).  Therefore,  we decided to extend  our 
analysis to resistant CBA and  C3H mice,  which were re- 
ported  to  develop  less  severe  and  more  quickly resolving 
lesions  than  C57BL/6  mice  after  infection with L.  major 
(28).  By immunohistology, iNOS was found both during 
the acute stage of infection (day 29) and after healing of the 
skin lesions (days 146 and 201) ha C3H and CBA mice (n = 
4; not shown). There was, however, an inverse correlation 
Figure 1.  Expression  ofiNOS protein in the lesional skin (A and B) and the popliteal lymph nodes (C-/'0 from C57BL/6 mice at various time points 
after infection with L. major  (3 X 106 into the footpad). The skin was analyzed  for the presence ofiNOS after clinical healing of  the lesions. (A-G) Anti- 
iNOS immunoperoxidase  labeling. In F, which is a consecutive  section of  E, the iNOS staining was blocked by the corresponding  iNOS peptide (10 Izg/ 
ml). In H, which is a consecutive section of G, NADPH diaphorase activity was visualized histochemicaUy. (A) ￿  (B) ￿  and (C-F) X 100, he- 
matoxylin counterstain. (G and/4)  X400, nuclear Fast red counterstain. 
1505  Stengcr et al. Table 1.  NOS Activity in the Lymph Node of Naive or 
L. major-infected C57BL/6 Mice 
C57BL/6 mice  Specific activity*  Total activity* 
Naive~  0.6 +  0.2  0.5 +  0.2 
Acutely infected  108.0  +  16.6  176.0  +  20.4 
(days 28-46)11 
Chronically infected  80.2 +  24.3  250.0 +  40.8 
(days 164-344)￿82 
*pmol NO2-/mg protein/min in a 120-min assay. 
*pmol NO2-/min per total lymph node. 
SMean _+ SEM of five lymph nodes from individual naive mice. 
IIMean +_ SEM of 16 popliteal lymph nodes from 11 infected mice that 
were derived from eight independent time course experiments (28--46 d 
after infection). 
￿82  -+ SEM of 13 pophteal lymph nodes from nine infected mice 
that were derived from five independent time course experiments (164- 
344 d after infection). 
between the degree of clinical resistance (C3H  >  CBA > 
C57)  and the amount of iNOS in the tissue of long-term- 
infected mice  (C57  >  CBA  >  C3H).  In fact,  no  iNOS 
protein was detected in the footpads from clinically cured 
C3H  mice.  The  imphcations  of this  finding will be  dis- 
cussed below. Persistence ofiNOS  was also observed in the 
lymph nodes of L,  major-infected BALB/c mice (days 267, 
292,  or 366  after infection; not shown),  which were  ren- 
dered resistant by low dose infection or by treatment with 
anti-CD4  or  IL-12  before  infection,  following pubhshed 
protocols  (29-31).  These  findings demonstrate  that  tissue 
expression ofiNOS  beyond the acute phase of L. major in- 
fection occurs in a number of different mouse strains. 
Persistence of iNOS Activity Is Dependent on  CD4  T  Cells. 
In cutaneous leishmaniasis of resistant mice, CD4 §  T  cells 
are indispensable for the control of the primary acute infec- 
tion (32), whereas both CD4 + and CD8 + T  cells contrib- 
ute to the resistance against reinfection (33).  To define the 
T  cell subpopulation that  is required  for maintaining the 
expression  of iNOS,  we  apphed  anti-CD4  or  anti-CD8 
Abs to long-term-infected resistant mice. The data in Ta- 
ble 2  demonstrate that depletion of CD4 + T  cells caused a 
80%  reduction of the specific NOS  activity in the lymph 
node.  This  was  also  confirmed  by  immunohistological 
Table 2.  Effect  of Anti-CD4 or -CD8 Treatment on the Cellular 
Composition and the NOS Activity in the Lymph Node of 
L. major-infected Mice 
In vivo treatment* 
Parameter  PBS  Anti-CD4  Anti-CD8 
Cellular composition 
Thy 1.2 +  32.0 +  3.9  21.3  +  2.8  21.5  +  5.9 
CD4 +  16.0  +  1.5  2.5 +  1.9  21.4 _+ 4.6 
CD8 +  13.4  -+ 2.3  18.9  +  3.3  1.4 +  0.3 
B220 +  57.1  -+ 5.0  66.8 +  2.3  66.5  +  6 
F4/80 +  1.4 +  0.4  2.2 +  1.3  1.5 +  0.4 
NOS activity 
Specific activity*  43 +  4  9 -+ 2  75 +  16 
Total activity~  195  +  47  13 -+ 7  283 +  46 
*Long-term-infected C57BL/6 mice (day 147 or 220 after bilateral in- 
fection into the footpad; four mice per group) were injected intraperi- 
toneally with PBS, anti-CD4, or anti-CD8 antibody (day +0, +2, +6, 
+10). After 14 d of treatment, lymph nodes were subjected to FACS  | 
analysis or NOS enzyme activity assays. Values denote  mean  +  SD 
from two independent experiments. 
*pmol NO2-/mg protein/min (120-min assay). 
Spmol NO2-/min per total lymph node. 
analysis of the lymph nodes (not shown).  In contrast, anti- 
CD8  treatment did not lead to a decrease, but rather to an 
increase of NOS activity (Table 2). 
Identification  of the Cells Expressing iNOS and~or Harboring 
L. major Parasites.  In clinically healed resistant mouse strains, 
a  small  number  of Leishmania  continue  to  reside  in  the 
draining lymph  node  (16,  21-24)  and  at  the  site  of the 
former skin lesion (33,  and  Fig.  2  A). Occasionally, para- 
sites are also found to persist in the spleen (20)  (see Fig. 2 
A).  To  address  the  issue  of how  the  parasites manage  to 
survive despite the continuous presence ofiNOS  in the tis- 
sue, we determined the phenotype of the cells, which ex- 
press  iNOS  and/or  carry  Leishmania  during  the  chronic 
stage of infection. By immunofluorescence double staining 
of single cell suspensions and double labeling of tissue sec- 
tions, iNOS was detected in distinct types of macrophages 
(F4/80 +,  BM-8 +,  and/or  MOMA-2+;  Fig.  3,  A  and  C) 
and in dendritic cells (NLDC-145+;  Fig. 3,  B  and D), but 
Figure 3.  Characterization of the cell types expressing  iNOS and/or carrying L. major  parasites/antigen in the popliteal lymph node of long-term-in- 
fected C57BL/6 mice. (A and/3) Double immunofluorescence labeling of a lymph node single cell suspension (day 157 after infection) partially depleted 
ofT and B cells as described in Materials and Methods. (A) Cell coexpressing  the F4/80 marker (green) and iNOS (red); (B) a NLDC145 + cell (green) that 
is also positive for iNOS (red). To visualize  the differentially  labeled markers on the same cell, slides  were gently moved (direction indicated by arrows) be- 
fore changing the fluorescence filters. Double (C-G) or triple (H-/) labeling of lymph node sectiom for iNOS (immunogold-silver staining, black), for 
cell-type marker (immunoperoxidase staining, brown), and/or for L. major  (alkaline  phosphatase staining, blue) without counterstain. (C) Colocalization of 
iNOS and MOMA-2 (macrophage), day 120. (D) Colocalization ofiNOS and NLDC-145 (dendritic cell), day 147. (E) L. major  and F4/80 plus NLDC- 
145, day 147. L. major  (blue) is localized outside the F4/80- or NLDC-145--positive cells. (F and G) L. major  and iNOS, day 378. L. major  (blue) inside (E) 
or outside (F) of  an iNOS cluster (black). (1-1) L. major, iNOS and F4/80, day 120, triple positive cluster. (1) L. major, iNOS and cell-type marker (Abs F4/ 
80, NLDC-145, MOMA-2, and Mac-1 were combined), day 120. L. major  (blue) is located outside the iNOS-positive macrophage/dendritic cell cluster. 
(A-D, F-H), and inset, E ￿  (Eand/) X400. 
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32+), B cells (B220+), or T cells (Thyl +) (not shown). The 
same conclusions were reached by labeling of consecutive 
sections with anti-iNOS or the anti--cell  type Abs, respec- 
tively (not shown). In accordance with previous data (24), 
L. major parasites were found in macrophages and dendritic 
cells (not shown). However, by combined staining of  tissue 
sections for L. major and F4/80 plus NLDC-145, Leishma. 
nia  were  also  identified in  areas  free  of F4/80  +  macro- 
phages and NLDC-145 + dendritic cells (Fig. 3 E). No par- 
asites  were found in granulocytes or endothelial cells  (not 
shown).  In  a  series of 34  lymph nodes from long-term- 
infected mice (106-580 d after infection) derived from 12 
independent time course experiments, 36% of 962 L. major 
foci detected colocalized with iNOS in the tissue  (Fig.  3 
F).  The majority of parasites (64%),  however, was clearly 
located outside the dusters of iNOS-positive cells  (Fig.  3 
G). Triple labeling experiments revealed that macrophages 
or dendritic cells, which harbored parasites  or parasite anti- 
gens, were also positive for iNOS (Fig. 3/-/). The Leishmania 
in the iNOS-negative areas, in contrast, did not colocalize 
with F4/80-, MOMA-2-, or Mac-l-positive macrophages 
or  NLDC-145--positive  dendritic  cells  (Fig.  3  /).  From 
these data we conclude that L. major parasites  might secure 
their survival in the host by entering an as yet unidentified 
type of cell in the absence ofiNOS induction. 
Continuous  Activity  of iNOS Is Required for the Control of 
L. major Parasites Persisting in Clinically Cured Mke.  The find- 
ings presented so far raised the possibility that the persis- 
tence of iNOS is functionally linked to the control of the 
residual parasites  in the tissue.  To test this hypothesis, we 
applied L-NIL to  long-term-infected mice.  The inactive 
D-enantiomer of L-NIL is not yet available in amounts suf- 
ficient for in vivo experiments, but clearly fails to inhibit 
iNOS  activity in vitro  (4,  34).  In contrast to the widely 
used  L-NMMA,  L-NIL is  an  inhibitor,  which  is  30--40 
times more selective for the inducible than for the constitu- 
tive isoform of NOS.  Furthermore, L-NIL is much more 
potent than t-NMMA and nontoxic in mice thus fax tested 
(4).  In  five  independent  experiments,  oral  treatment  of 
clinically cured C57BL/6 mice with L-NIL (4.5 or 9 mM 
in the drinking water, started at day 103, 123, 130, 139, or 
244 of infection) led to a massive increase in the numbers 
of parasites  in the footpad and popliteal lymph node as de- 
termined by limiting dilution analysis (Table 3) and immu- 
nohistology  (Fig.  4,  A  vs.  B).  Most  importantly,  L-NIL 
caused the reappearance of cutaneous lesions in  13 out of 
14 mice within 7-20 d of treatment (Fig. 5). Functional in- 
activation of iNOS was further demonstrated by a >90% 
suppression of enzyme activity (Table 4), and the colocal- 
ization  of iNOS  protein  and  clusters  of parasites  in  the 
lymph node of L-NIL-treated mice. In serial sections from 
control  lymph  nodes,  in  contrast,  only  a  few  scattered 
Leishmania were present in areas  of iNOS expression (Fig. 
4, A  vs.  C  and B vs. /9). Despite the tremendous parasite 
burden in the skin and draining lymph node and the devel- 
opment of severe and eventually exulcerating lesions after 
treatment with t-NIL, dissemination into the spleen and/ 
Table  3.  Effect of L-NIL on the Parasite Burden in the Tissues of 
L. major-infected C57BL/6, C3H, and CBA Mice as Determined 
by Limiting Dilution AnaiFsis* 
Group  Parasites  Parasites per 
of  mice  t-NIL  per organ*  1,000 cells$ 
C57BL/6 
Footpad 
Lymph 
node 
C3H 
Footpad 
Lymph 
node 
CBA 
Footpad 
Lymph 
node 
-  6.1 (4.9-7.3)  X 10  na 
+  3.4 (2.4--4.4) X 10q  na 
-  1.2 (0.9-1.3)  ￿  10  3  1.7 (1.4--1.9) X 10  -2 
+  3.8 (2.6-5.0)  X 107U  3.2 (2.2--4.2) ￿  102 
-  nd  na 
+  nd  na 
-  1.5  (1.0--1.9)  X  102  9  (6-11)  X  10 -3 
+  1.5 (0.9-2.0)  X 10q  3.7 (2.3-5.1) 
-  5.3 (3.1-7.5)  X 10  na 
+  7.8 (6.7--8.8) X 103~  na 
-  4.7 (3.3-6.0)  X 102  6 (4--8) X 10  -2 
+  1.5 (0.9-2.0)  X 10nil  3.7 (2.3-5.1) 
*Mice were infected with 3  X 106 parasites into the hind footpads. 
Groups of  four mice were kept on normal water or treated with L-NIL 
(4.5 mM in the water) for 42 d starting at day 103 of infection when 
the primary  lesiom had healed (see Fig. 7). 
*95% confidence  interval  is given in parentheses. ND, no parasites de- 
tectable in the undiluted footpad homogenate (3 ml per footpad; 100 
Ixl homogenate/well). 
SCalculated from the total number of  cells per lymph node. 
USignificant difference  when compared with the corresponding  control 
group (significance  was assumed when the 95% confidence  limits did 
not overlap). 
NA = not applicable. 
or reactivation of latent Leishmania  in the spleen was ob- 
served in only two of five experiments and to a very lim- 
ited extent (the increase of the parasite burden caused by 
L-NIL was <20-fold). When the application of t-NIL was 
discontinued, the lesions regressed and finally healed (not 
shown). 
In  parallel  to  L-NIL, we also  tested  the  effect  of  L-NAME, 
an inhibitor with strong selectivity for the constitutive iso- 
form of NOS, and of L-NMMA (which inhibits inducible 
and constitutive NOS) (35) in long-term--infected C57BL/6 
mice. L-NAME and its inactive D-analogue failed to elicit 
recrudescence of the disease.  Administration of L-NMMA 
(but not of D-NMMA) caused reappearance of leishmanial 
lesions similar to L-NIL Both L-NAME- and L-NMMA- 
treated  mice  showed  signs  of severe  drug  toxicity (e.g., 
weight loss,  reduced fluid, and food uptake)  (Fig.  5).  For 
L=NIL,  in  contrast, careful monitoring of body weight as 
1508  Reactivation of  Leishmaniasis by Inhibition of  Synthase Nitric Oxide l~igure 4.  Effect  oft-NIL on the expre-~on  ofiNOS and presence  ofL. majorparas  in the lymph  node of  C57BL/6 mice (day  168 after  infection). 
(A and C) Consecutive  sectiom  f~om  control  mice kept on normal  water. (B and D) Consecutive  sectiom  from mice kept on water  with 9 mM L-NIL 
from days 139 to 168. (A and B) Anti-L. major, (C and D) anti-iNOS. (A-D) ￿  100; (insets  B and C) X 1,000. 
well as food and fluid uptake did not reveal any alterations 
compared with  the  control group  kept  on normal water 
(Fig.  5) which closely resembles our recently published re- 
suits  on the effect of L-NIL versus L-NMMA in C57BL/6 
mice during the acute phase of L.  major infection (4). 
Finally,  we  investigated the  effect of t-NIL  on  long- 
term-infected CBA and C3H mice, which had healed their 
cutaneous lesions (day 103 or 149 of infection). As was the 
case in C57BL/6 mice, a small amount of L.  major parasites 
persisted in the draining lymph node of  both strains,  which 
strongly increased upon treatment with t-NIL (Table 3). In 
CBA mice, residual parasites  were also detectable at the site 
of the former skin lesion (Table 3), which presumably are 
responsible for the  recurrence of clinical disease  (footpad 
swelling)  after treatment with t-NIL in six of seven mice 
from two independent experiments (Fig. 6). In contrast, no 
Leishmania were grown from the footpad tissue of  nine clini- 
cally cured C3H mice, individually tested by limiting dilu- 
tion analysis at the end of a 42-52-d period during which 
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the mice were either kept on normal drinking water or on 
water supplemented with L-NIL (Table 3). Consequently, 
reactivation of cutaneous leishinauiasis  was  only observed 
in one of eight C3H mice treated with L-NIL (Fig.  6, and 
data not shown). The spleens of control or t-NIL-treated 
CBA or C3H mice were routinely negative for parasites  in 
our detection system (not shown). 
Together, these results indicate that inducible, but not 
constitutive NOS, is required for the control of persisting 
Leishmania.  Parasite  replication and  recrudescence of the 
disease  after inhibition of iNOS  seems to be confined to 
the sites where live parasite remained after resolution of  the 
acute phase of  infection. 
Discussion 
In a previous in vitro study, reactivation of Epstein-Barr 
virus replication in human B cell lines was shown to be in- 
hibited by endogenous NO  (36).  In the present paper we Q 
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Figure 5.  Reactivation of cu- 
taneous lesions in C57BL/6 mice 
after treatment with inhibitors of 
iNOS.  15  mice  were  infected 
with L  major (3 X 106) into the 
right  hind  footpad. From  day 
123 of infection onwards, mice 
were either kept on normal wa- 
ter  or  treated for  36  d  with 
t-NIL (4.5 raM), L-NMMA (50 
raM),  D-NMMA (50  raM), or 
t-NAME (50 raM). Lesion de- 
velopment (mean +  SEM, three 
mice per group; where error bars 
are not visible, they fall within 
the  symbols) was  monitored. 
The mean (+_ SD) food and wa- 
ter  consumption and  the  mean 
(+  SD)  percent  weight  gain 
(= [weight at day 159 -  weight 
at day 123] : weight at day 123 
X 100%) during treatment is also 
given.  Negative numbers de- 
note weight loss. (~ *) Significant 
decreases compared with  con- 
trol (Student's t test for unpaired 
samples; * P <0.001, * P <0.01). 
provide the first direct in vivo evidence for NO-dependent 
control of an intracellular microogranism in a latently in- 
fected host organism. In clinically cured, L.  major-infected 
resistant mice, small numbers of Leishmania are found in the 
draining lymph node (21-24) and, depending on the mouse 
strain, also at the site of the former skin lesion (33, and Fig. 
2 A  and Table 3). Persistence of  parasites is accompanied by 
the continuous expression ofiNOS in the respective tissue, 
which presumably lasts for life. Although the systemic uri- 
nary excretion  of reactive  nitrogen  intermediates  was re- 
ported  to  drop  after  healing  of the  cutaneous  lesions  in 
Table  4.  Suppression of NOS Activity by L-NIL in the Lymph 
Node of C57BL/6 Mice Chronically Infected with L. major* 
Treatment  Specific activity*  Total activityS 
None[I  106 -+ 37  304 -+ 51 
r-NIDI  5 -+ 1.8  30 -+ 8 
*Values denote mean + SEM of  eight popliteal lymph nodes from four 
L. major-infected mice per group that were derived from two indepen- 
dent in vivo experiments (day 277 or 344 after infection). 
*pmol NO2-/rng protein/rain  in a 120-min assay. 
Spmol NO2-/min per total lymph node. 
IIMice were kept on drinking water with or without t-NIL (4.5 mM) 
for 9 d before analysis of  the lymph nodes. 
L. major-infected  C3H mice (18), the results of our in situ 
analysis  clearly  demonstrate  that  the  local  expression  of 
iNOS is maintained  at levels similar to the acute phase of 
infection. By double labeling techniques, both macrophages 
and  dendritic  cells  were  found  to  express  iNOS  in  the 
lymph node. The expression of iNOS in vivo by dendritic 
cells has not been reported before. Based on several obser- 
vations, the iNOS protein in the tissue does not represent 
amyloid-like, functionally inactive debris left over from the 
previous inflammatory response.  First, iNOS was not only 
detected by the Ab directed  against the COOH  terminus 
of the protein, but also by an Ab against amino acid 13-22 
of the NH2-terminal mouse iNOS sequence  (Bogdan, C., 
and  N.  Donhauser,  unpublished  results).  Second,  persis- 
tence  of iNOS  expression  was  confirmed  on the  level of 
mRNA.  Third,  determination  of NOS  activity  in  the 
lymph node yielded values in the same order of magnitude 
during the  acute  and  chronic  stages  of infection.  Fourth, 
expression  of iNOS  protein  always  coincided  completely 
with NADPH-diaphorase activity at early (9) and late time 
points after infection (Fig. 1).  Finally, application oft-NIL, 
an inhibitor with relative selectivity for iNOS,  led to the 
reactivation  of parasite  replication  and  resurgence  of dis- 
ease, whereas t-NAME, an inhibitor of constitutive NOS, 
was inactive in this respect. This indirecdy proves the pres- 
ence of functionally active iNOS.  It is interesting  to note 
that the reappearance of cutaneous lesions and/or the  103- 
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Figure  6.  Effect of t-NIL  on  the 
healed cutaneous lesions of CBA and 
C3H mice. Eight C3H and eight CBA 
mice were infected with L. major (3 ￿ 
106  ) into the right hind footpad. From 
day 103  after infection onwards, mice 
were either kept on normal water or 
treated for 42 d with t-NIL (4.5 raM). 
Lesion development (mean  -+  SEM, 
four mice per group) was monitored. 
Weight development, as  well as  food 
and water consumption, was not altered 
by t-NIL (not shown). 
104-fold increase  of the numbers  of Leishmania in  the  re- 
gional lymph nodes ofC57BL/6, CBA, and C3H mice after 
treatment with L-NIL never led to overwhelming visceral 
leishmaniasis with  a high parasite burden  in  the  spleen as 
seen during the progressive infection of highly susceptible 
BALB/c  mice.  As iNOS  mRNA  and  protein  were  only 
weakly expressed in the spleen of long-term-infected mice 
(not  shown),  our  findings  suggest  the  existence  of NO- 
independent control mechanisms in this organ. 
The persistence of iNOS in the lymph node of clinically 
cured mice raises questions about the stimuli underlying the 
continuous  upregulation  of iNOS.  Our data  demonstrate 
that  CD4 + but not  CD8 +  T  cells  are required  for main- 
taining  expression  of iNOS.  Although  the  depletion  of 
CD4 +  T  cells  led  to  a  75-80%  decrease  of the  specific 
NOS activity (Table 2) and to an increased number of par- 
asites  in  the  respective lymph node  sections  (not shown), 
this was not yet sufficient to cause reappearance of cutane- 
ous lesions within the 10-14 d of  Ab application and obser- 
vation. Previous studies, however, have already shown that 
prolonged treatment with anti-CD4 (>20-25 d) will reac- 
tivate latent leishmaniasis in resistant mice (37).  Consider- 
ing the pivotal role ofIFN-~/for the induction ofiNOS in 
vivo  (38,  39)  and  the  exacerbative  effect  of anti-IFN-~ 
during acute leishmaniasis and in clinically cured L.  major- 
infected  mice  (40,  41),  it  is  likely  that  the  reduction  of 
NOS  activity by anti-CD4  at least partially results from a 
lack of IFN-% As cells other than CD4 + T  cells are known 
to produce IFN-~/ (e.g., NK or CD8 + T  cells),  and multi- 
ple  cytokines cooperate with  IFN-~/ for the  induction  of 
iNOS  (for a  review see reference 42),  it is not surprising 
that inhibition ofiNOS by L-NIL is by far more efficient in 
reactivating clinical disease  than anti-CD4 treatment. 
Given  the  susceptibility  of L.  major promastigotes  (10, 
11) and amastigotes to native NO or NO donors (Bogdan, 
C.,  A.  Diefenbach,  and  M.  Rrllinghoff,  manuscript  in 
preparation),  it  is  unexpected  that  some parasites  survive 
despite the abundance ofiNOS in the tissue.  So far, there is 
no evidence for irreversible genetic alterations or for an in- 
crease of virulence during latency (23).  The recrudescence 
of leishmaniasis  seen  after inhibition  of iNOS  by L-NIL 
further demonstrates that persistent L.  major obviously do 
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not acquire overt resistance to NO, but remain susceptible 
to the direct or indirect antileishmanial effects of NO. Our 
in situ analysis,  however, offers some ideas of how Leishma- 
nia might manage to survive in  the tissue.  60-70%  of the 
parasites persisting in the lymph node were located in areas 
that  were  negative for iNOS  and  for known  markers  of 
macrophages (F4/80, BM-8, MOMA-2, Mac-l), dendritic 
cells  (NLDC-145),  granulocytes  (GR-1),  or  endothelial 
cells  (MECA-32).  Within  the inherent limits of immuno- 
histological  analyses  (e.g.,  it  is  impossible  to  recognize  a 
double positive cell when two colors are exactly superim- 
posed), our findings suggest the existence of a novel type of 
host cell, which either intrinsically or due to suppression by 
parasite  products  (43)  lacks  the  production  of NO  and 
therefore might serve as a "safe target" (44) for L.  major. It 
is possible that the Leishmania reside in a subtype of tissue 
macrophages (histiocytes) that is not picked up by the tested 
Abs.  Alternatively,  the  parasites  might  infect  fibroblasts. 
The latter possibility is suggested by the large amounts of 
collagen fibers and extracellnlar matrix components in the 
chronically infected lymph nodes (Bogdan, C., N. Donhauser, 
and S. Stenger, unpublished results). In vitro, L. braziliensis 
efficiently entered fibroblasts, but became lodged in vacu- 
oles that did not fuse with secondary lysosomes and thereby 
could evade killing by the host cell (45). 
Approximately 30--40% of the L.  major (antigen)  foci in 
the lymph nodes of  long-term-infected mice colocalized with 
iNOS-positive macrophages or dendritic cells. Whereas we 
cannot prove NO-mediated killing of the parasites in situ, 
this  observation indicates  an intimate interaction between 
iNOS-positive (host) cells and L. major. Our results support 
the  idea  that parasite killing and  evasion are permanently 
ongoing in the lymph nodes  of long-term-infected mice. 
The CD4-dependent persistence of iNOS,  the concurrent 
expression ofcytokines (IL-4, IFN-% TGF-~3) in the latent 
lesions  (Stenger,  S.,  and  C.  Bogdan,  unpublished  results) 
and  the  presence  of L.  major parasites  or antigen  in  botll 
iNOS-negative  and  -positive areas  strongly suggest a  dy- 
namic, long-lasting inflammatory process and argue against 
a static dormancy of the microorganisms. 
From  a  teleological  point  of view  one  might  wonder 
why the host organism allows persistence rather than clear- ance of parasites with the result of a lifelong inflammation 
in the  tissue.  It has  been proposed that  the  presence  of a 
few viable Leishmania might be required  to maintain  pro- 
tective immunity to reinfection (33), following the notion 
that T  cell memory is short-lived in the absence of antigen 
(46). It is also intriguing to speculate that the sustained lev- 
els  of iNOS  after infection with  an intracellular  microor- 
ganism might enhance the resistance of the host against un- 
related,  but  NO-sensitive  pathogens.  In this  context  it  is 
worthwhile  to reconsider earlier  studies  that demonstrated 
resistance  to  bacterial  or  fungal  infections  (e.g.,  Listeria 
monocytogenes, Cryptococcus neoformans) or to malignant tumors 
in mice latently infected with  Toxoplasma gondii (47--49). 
Reduced activity of iNOS might be the mechanism un- 
derlying  the  reactivation  of leishmaniasis  in  immunosup- 
pressed mice and humans.  Cutaneous lesions reappeared in 
clinically cured C57BL/6 mice after a 3-wk treatment with 
cyclophosphamide or hydrocortisone (16). Glucocorticoids 
have been shown to suppress the cytokine-induced induc- 
tion of iNOS in macrophages and other cells  (50 and refer- 
ences therein).  Several  cases  of visceral leishmaniasis  have 
been noted in immunosuppressed persons many years after 
they have moved from endemic areas, which strongly sug- 
gests that endogenous reactivation of Leishmania replication 
also occurs in humans  (17,  51,  52).  In addition,  evidence 
has emerged that human monocytes/macrophages control 
L. major parasites in an NO-dependent manner (53). 
In conclusion,  the  experiments  presented  here  demon- 
strate  that  the  expression  of iNOS  by  macrophages  and 
dendritic cells is crucial for maintaining a state of long-term 
resistance  against  latent  Leishmania.  We  believe  that  our 
findings will also apply to infections with other NO-sensi- 
tive  intracellular  microbes including viruses  that persist  in 
the host after resolution of the acute disease. 
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